Wednesday 15 Apr 2026 @ 16:05
National Institute for Health and Clinical Excellence (NICE)
Printable version

Have your say on NICE’s adoption of the new EQ-5D-5L value set

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of life.

The consultation is now open, and we encourage patients, clinicians, industry representatives, academics and other stakeholders to share their views. 

The EQ-5D is a short questionnaire used to understand how a person's health affects their quality of life. Responses to the questionnaire are converted into a single number (called a utility value) using a mathematical model called a value set. We use utility values in our cost-effectiveness evaluations, to assess whether an intervention offers value for money.  

NICE has to date been using an old value set, based on data that was collected in the early 1990s. The new UK EQ-5D-5L value set offers a more accurate reflection of how people in the UK think about health and quality of life today.  

To find out more about the EQ-5D-5L read the blog by Sophie Cooper, senior scientific adviser.

Our assessments use quality-adjusted life years (QALYs) to estimate the health benefits of new medicines. The QALY combines both the length of life gained from a treatment and its impact on quality of life compared with current treatment. The current consultation includes proposed updates to NICE's methods manuals, along with the results of 3 impact assessments examining how the EQ-5D-5L could affect: 

  • cost-effectiveness calculations, including QALY estimates and incremental cost-effectiveness ratios 

  • the number of decisions qualifying for the severity modifier and how it changes QALY shortfall estimates 

  • equalities and health inequalities.

We’re proposing these changes through our modular updates process. 

Your response could help shape how NICE evaluates treatments for years to come. More accurate measurements mean better decisions - and better decisions mean patients get access to the treatments that truly matter. 

The consultation is open from Wednesday 15 April to Wednesday 13 May.

Channel website: https://www.nice.org.uk/

Original article link: https://www.nice.org.uk/news/articles/have-your-say-on-nices-adoption-of-the-new-eq-5d-5l-value-set

Share this article

Latest News from
National Institute for Health and Clinical Excellence (NICE)

‘Trojan horse’ treatment recommended for people with multiple myeloma

16/04/2026 16:20:00

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).

Changes to NICE’s cost-effectiveness thresholds take effect

06/04/2026 10:20:00

NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments.

NHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with USA

06/04/2026 09:26:00

New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life sciences industry investment

Injection for more than a million people to help prevent heart attacks and strokes recommended

01/04/2026 16:05:00

People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.

NICE recommends new dedicated fertility treatment pathway for endometriosis

01/04/2026 09:15:00

The updated fertility guideline includes a brand-new section specifically for those with endometriosis who are struggling to conceive – published to coincide with the final day of Endometriosis Action Month.

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

11/03/2026 16:05:00

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable.

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

10/03/2026 14:15:00

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

Driving biosimilar adoption through collaboration

02/03/2026 16:15:00

How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.

NICE publishes first quality standard to improve care for people with rare diseases

27/02/2026 17:10:00

Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.

Conference 2026